{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"642"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.","groups":[{"description":"The usual adult dosage for oral administration was 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle was repeated for 6 cycles. The dose might be reduced appropriately according to the patient's condition. Participants received interventions as part of routine medical care.","id":"OG000","title":"Ixazomib 4 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey.","reportingStatus":"POSTED","timeFrame":"Up to 24 Week (From start of administration to the end of 6 cycles)","title":"Number of Participants Reporting One or More Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}